The treatment of deep vein thrombosis with continuous intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study

Thrombosis Research

Volumn 84, Issue 6, 1996, Pages 391-398

  Kretz, Jean George ^b   Chakfe, Nibal ^b   Wiesel, Marie Luise ^b   Grunebaum, Lélia ^b   Zamboni, Villiam ^a   Palazzini, Ernesto ^a   Cazenave, Jean Pierre ^b  

^a Alfa Wassermann SpA   (Italy)

^b NONE

Author keywords

deep vein thrombosis; intravenous administration; low molecular weight dermatan sulphate; therapy

Indexed keywords

DESMIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DERMATAN SULFATE; DESMIN; FACTOR XA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; THROMBOPHLEBITIS;

EID: 0030589710     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(96)00207-1     Document Type: Article

References (34)

1. BAKER W.F. Outcome analysis for treatment in 100 patients with Deep Vein Thrombosis. Clin Appl Thrombosis/Haemostasis. 1(1):1995;39-48.
2. SALZMAN EW, DEYKIN D., SHAPIRO RM., ROSENBERG R. Management of heparin therapy: controlled prospective trial. N Eng. J. Med. 292, 1046-50, 1975.
3. MOSER KM. Venous thromboembolism: state of the art. Am Rev Respir Dis 141, 235-49, 1990.
4. HULL RD. Anticoagulant treatment. Intern Ang 14, 32-441, 995.
5. MASCELLANI G, BIANCHINI P. European Patent 1990, N. 0221977. USA Patents N. 4973580, 1990.
6. TAMAGNONE G, BARBANTI M. Desmin 370. Drugs Fut. 19:1994;638-640.
7. BARBANTI M, CALANNI F, BABBINI M, BERGONZINI G, PARMA B, MARCHI E Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res. 71:1993;417-422.
8. BARBANTI M, CALANNI F, MILANI MR, MARCHI E, SEMERARO N, COLUCCI M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant-independent mechanism. Thromb Haemost. 69:1993;147-151.
9. BARBANTI M, CALANNI F, MARCHI E, SEMERARO N, COLUCCI M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rat: comparison with t-PA and u-PA. Thromb Haemost 69, Abstr. 860, 1993.
10. COLUCCI M, TRIGGIANI R, CAVALLO LG, CHIUMARULO P, BARBANTI M, SEMERARO N. Therapeutic effect of a LMW-dermatan sulfate in experimental venous thrombosis. Comparison with hirudin and heparin. Fibrinolysis. 6:1992;136-140.
11. BARBANTI M, CALANNI F, MARCHI E, SEMERARO N, COLUCCI M. Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of preformed thrombi in rats made afibrinogenemic by Ancrod. Thromb Haemost. 73(2):1995;287-290.
12. DETTORI AG, GALLI G, MANOTTI C, PALAZZINI E Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Sem Thromb Hemost. 20:1994;259-265.
13. DETTORI AG, MANOTTI C, PALAZZINI E, ZAMBONI V, MILANI MR, BARBANTI M Pharmacology of Desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb Res. 79:1995;249-260.
14. LEGNANI C, PALARETI G, BIAGI R, LUDOVICI S, MAGGIORE L, MILANI MR, COCCHERI S Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharm. 47:1994;247-252.
15. CUCINOTTA D, MANOPULO R, GALATI M, ZAMBONI V, PALAZZINI E, BARBANTI M, MILANI MR Pharmacodynamics of a new low-molecular-weight dermatan sulfate after a single subcutaneous injection in elderly patients with chronic venous disorders: a Phase I trial. Curr Ther Res. 55:1994;1492-1500.
16. TRAINI AM, CERVI V, MELANDRI G, PALAZZINI E, ZAMBONI V, SEMPRINI F, CANDIOTTI N, BRANZI A. Pharmacodynamic characteristics of a low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction. J Intern Med Res. 22:1994;323-331.
17. MARDER VJ, SOULEN RL, ATICHARTAKARN V, BUDZYNSKI AZ, PARULEKAR S, KIM JR, EDWARD N, ZAHAVI J, ALGAZY KM. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med. 69(5):1977;1018-1029.
18. CAEN J, LARRIEU MJ, SAMAMA M (Eds). L'hémostase. Méthodes d'exploration et diagnostic pratique. Expansion Scientifique (2èmemédition). Paris (1975).
19. GALLUS AS, JACKAMAN J, TILLET J, MILLS W, WYCHERLEY A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 2, 1293-6, 1986.
20. HULL RB, RASKOB GE, ROSENBLOOM D, PANJU AA, BRILL-EDWARDS P, GINSBERG JS, HIRSH J, MARTIN GJ, GREEN D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322, 1260-4, 1990.
21. HULL RB, RASKOB GE, HIRSH J, RICHARD MJ, LECLERC JR, WILLIAM HG, ROSENBLOOM D, SACKETT DL, ANDERSON C, HARRISON L, GENT M Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N. Engl J Med. 315:1986;1109-1114.
22. WILSON JR, LAMPMAN J. Heparin therapy: A randomized prospective study. Am Heart J 97 115-8, 1979.
23. GALLUS AS Overview of the management of thrombotic disorders. Semin Thromb Hemost. 15:1989;99-110.
24. HOMMES DA, BURA A, MAZZOLAI L, BULLER HR, TEN CATE JWD Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann. Int. Med. 116(4):1992;279-284.
25. WARKENTIN TE, LEVIN MN, HIRSH J, HORSEWOOD P, ROBERT RS, TECH M., GENT M, KELTON JG. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Eng J Med 332, 1330-5, 1995.
26. ASTER RH. Heparin-induced thrombocytopenia and thrombosis N Eng J Med 332, 1374-6, 1995.
27. PRANDONI P, LENSING AW., BULLER HR, CARTA M, COGO A, VIGO M, CASARA D, RUOL A, TEN CATE JW. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 33, 441-5, 1992.
28. SIMONNEAU G., CHARBONNIER B, DECOUSUS H, PLANCHON B, NINET J, SIE P, SILSIGUEN M, COMBE S. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis Arch Intern. Med 153, 1541-6, 1993.
29. GREEN D, HIRSH J, HEIT J, PRINS M, DAVIDSON B, LENSING AWA Low molecular weight heparin: a critical analysis of clinical trials. Pharmacological review. 46(1):1995;89-109.
30. LENSING AWA, PRINS MH, DAVIDSON BL, HIRSH J. Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med. 155:1995;601-607.
31. HULL RD, RASKOB GE, PINEO GF, GREEN D, TROWBRIDGE AA, ELLIOT G, LERNER RG, HALL J, SPARLING T, BRETELL HR, NORTON J, CARTER CJ, GEORGE R, MERLI G; WARD J, MAYO W, ROSENBLOOM, D, BRANT R. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal vein thrombosis. N. Engl J Med 325, 975-82, 1992.
32. WEINMANN EE, SALZMAN EW. Deep Vein Thrombosis. N Eng J Med 331, 1630-41, 1994.
33. LEVINE M, GENT M, HIRSH J, LECLERC J, ANDERSON D, WEITZ J, GINSBERG J, TURPIE AG, DEMERS C, KOVACS M, GEERTS W, KASSIS J, DESJARDINS L, CUSSON J, CRUICKSHANK M, POWER P, BRIEN W, HALEY S, WILLAN A. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N. Engl J Med 334, 667-81, 1996.
34. KOOPMAN MMW, PRANDONI P, PIOVELLA F, OCKELFORD PA, BRANDJES DPM, VAN DER MEER J, GALLUS AS, SIMONNEAU G, CHESTERMANN CH, PRINS MH, BOSSUYT PMM, DE HAES H, VAN DEN BELT AGM, SAGNARD L, D'AZEMAR P AND BULLER HR FOR THE TASMAN STUDY GROUP. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 334, 682-87, 1996.